What does PNC-27 stack well with?

For body composition / training protocols, PNC-27 pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from PNC-27's primary mechanism (Composed of the p53 transactivation domain fused to a membrane-residence peptide), producing additive or synergistic effects rather than receptor competition.

What is the evidence base for PNC-27?

PNC-27's evidence base sits at preclinical + case reports. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How long until I see results from PNC-27?

Acute effects from PNC-27 appear within the first week for downstream physiological adaptation. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What class of compound is PNC-27?

PNC-27 is classified as a Anti-cancer membrane-disrupting peptide. Within this class, alternative names and analogues include Penetrating peptide 27. The class-level pharmacology shapes both the clinical applications and the safety profile; the body composition / training literature treats PNC-27 alongside its class peers when evaluating relative merits.

Home/ Compounds/ PNC-27

PNC-27

Body Composition

Body composition response to PNC-27 is proportional to training stimulus and nutritional input. An experimental peptide that combines the p53 transactivation domain with a membrane-penetrating sequence — selectively disrupts cancer cell membranes in preclinical models. The compound contributes to the anabolic substrate, recovery window, or structural-adaptation layer depending on where its primary pharmacology acts. For trained athletes, the typical 8-12 week PNC-27 cycle produces visible composition shifts at week 4-8 with the standard 1-5 mg daily, varies by protocol dose.

Body Composition / Training Applications

Lean MassStrengthFat LossMuscle EnduranceInjury Recovery

Key Takeaways

Body composition lens: response to PNC-27 is proportional to training stimulus and nutritional adequacy.
Mechanism: Composed of the p53 transactivation domain fused to a membrane-residence peptide.
Body composition dose: 1-5 mg daily, varies by protocol via iv/subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Composed of the p53 transactivation domain fused to a membrane-residence peptide. Binds HDM-2 expressed at the cancer cell membrane and forms pore-like disruptions. Selective for transformed cells because HDM-2 surface expression is largely cancer-specific. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by PNC-27.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. PNC-27 with a Variable half-life of Variable is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where PNC-27 demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Recovery window and training frequency

The most reliably reported effect of PNC-27 in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Body Composition / Training Applications

Recovery

For recovery, PNC-27 integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Endurance

Endurance responds to PNC-27 with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Lean Mass

The body composition community converges on PNC-27 for lean mass with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Muscle Endurance

For muscle endurance, PNC-27 integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	IV	1-5 mg	8–12 weeks on / 4 weeks off
Conservative starter	IV	1-5 mg	4–6 weeks initial cycle
Body Composition focus	IV	1-5 mg	Daily, varies by protocol
Maintenance phase	IV	1-5 mg	Ongoing with periodic pauses

Dose timing for PNC-27 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

PNC-27 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

PNC-27 + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with PNC-27's mechanism in body composition / training protocols.
PNC-27 + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with PNC-27's mechanism in body composition / training protocols.
PNC-27 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with PNC-27's mechanism in body composition / training protocols.
PNC-27 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with PNC-27's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + case reports

Limited human safety data. Used in experimental oncology protocols only.

Lens-specific safety considerations for body composition / training use of PNC-27: Limited human safety data. Used in experimental oncology protocols only. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

PNC-27 — selective cancer cell membrane disruption

PMID 23393365

PNC-27 vs Related Peptides

Compound	Profile	Onset	Best For
PNC-27	Anti-cancer membrane-disrupting peptide	Variable	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Best stack pairing for lean mass?

The canonical lean mass stack pairs PNC-27 with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

How does PNC-27 compare to AAS for body composition?

Peptide therapeutics including PNC-27 produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

What is PNC-27?

PNC-27 (also known as Penetrating peptide 27) is a 32-residue anti-cancer membrane-disrupting peptide with a molecular weight of ~3600 Da and a plasma half-life of Variable. Composed of the p53 transactivation domain fused to a membrane-residence peptide. Binds HDM-2 expressed at the cancer cell membrane and forms pore-like disruptions. Selective for transformed cells because HDM-2 surface expression is largely cancer-specific. The compound is studied primarily in the body composition / training domain for the applications outlined above.

What is the standard dosing protocol for PNC-27?

Conventional PNC-27 dosing is 1-5 mg daily, varies by protocol via iv/subq. For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a PNC-27 Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified PNC-27 and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: ~3600 Da
Sequence length: 32 aa
Half-life: Variable
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + case reports

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for PNC-27 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for PNC-27

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised